The Landmark Bremelanotide (Vyleesi) FDA Approval
The Vyleesi FDA approval in 2019 marked a significant milestone in women's sexual health, offering a new treatment option for premenopausal women with hypoactive sexual desire disorder (HSDD). Bremelanotide, marketed as Vyleesi, is a melanocortin receptor agonist and the first of its kind to be approved for this condition. This article delves into the specifics of Vyleesi's FDA approval, its mechanism of action, clinical trial data, and its place in the landscape of female sexual dysfunction treatments.
Understanding Hypoactive Sexual Desire Disorder (HSDD)
HSDD is a common sexual dysfunction characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. It is a complex condition with biological, psychological, and social factors. Before the Vyleesi FDA approval, treatment options for HSDD were limited, leaving many women without effective solutions.
The Path to Vyleesi FDA Approval
The journey to the Vyleesi FDA approval involved extensive clinical trials to evaluate its efficacy and safety. The RECONNECT studies, two Phase 3, randomized, double-blind, placebo-controlled trials, were pivotal in the approval process. These studies assessed the efficacy and safety of bremelanotide in premenopausal women with HSDD. PMID: 31599840
Clinical Trial Results
The RECONNECT studies demonstrated that bremelanotide significantly improved sexual desire and reduced distress in premenopausal women with HSDD. The co-primary efficacy endpoints were the change from baseline in the Female Sexual Function Index-Desire Domain (FSFI-D) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13. The results showed statistically significant improvements in these measures for women treated with Vyleesi compared to placebo. PMID: 31599840
| Feature | Vyleesi (Bremelanotide) | Placebo |
|---|---|---|
| Mechanism of Action | Melanocortin Receptor Agonist | Inactive Substance |
| FSFI-D Improvement | Statistically Significant | Minimal |
| FSDS-DAO Improvement | Statistically Significant | Minimal |
How Vyleesi Works
Vyleesi is a synthetic analog of the naturally occurring peptide hormone alpha-melanocyte-stimulating hormone (α-MSH). It works by binding to melanocortin receptors in the central nervous system, which are thought to play a role in regulating sexual desire and arousal. Unlike other treatments for sexual dysfunction, Vyleesi is an on-demand treatment, taken as a subcutaneous injection at least 45 minutes before anticipated sexual activity. FDA.gov
Safety and Side Effects
The most common side effects reported in clinical trials were nausea, flushing, injection site reactions, and headache. Nausea was the most frequently reported side effect, but it was generally mild to moderate in severity and tended to decrease with subsequent doses. The FDA label also includes a warning for a transient increase in blood pressure and a reduction in heart rate. PMID: 35147466
The specialists at TeleGenix can help you understand if Vyleesi is the right treatment for you. Their team of experts can provide personalized guidance and support.
Vyleesi vs. Addyi
Before the Vyleesi FDA approval, Addyi (flibanserin) was the only FDA-approved treatment for HSDD in premenopausal women. However, there are key differences between the two medications.
| Feature | Vyleesi (Bremelanotide) | Addyi (Flibanserin) |
|---|---|---|
| Administration | Subcutaneous Injection (as needed) | Oral Tablet (daily) |
| Mechanism of Action | Melanocortin Receptor Agonist | Serotonin Receptor Agonist/Antagonist |
| Alcohol Interaction | No Contraindication | Contraindicated with Alcohol |
Internal Links
For more information on related topics, please visit the following pages:
References
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. PMID: 31599840
- VYLEESI (bremelanotide injection) Label. FDA.gov
- Safety Profile of Bremelanotide Across the Clinical Development Program. PMID: 35147466
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment.
